PSA screening and deaths from prostate cancer after diagnosis - A population based analysis

Prostate

Volumn 73, Issue 12, 2013, Pages 1365-1369

  Wachtel, Mitchell S ^a   Nelius, Thomas ^b   Haynes, Allan L ^b   Dahlbeck, Scott ^a   De Riese, Werner ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

mortality; prostate cancer; PSA; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CAUCASIAN; DISEASE ASSOCIATION; HEALTH PROGRAM; HUMAN; MALE; NEGRO; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; STANDARD;

MORTALITY; PROSTATE CANCER; PSA; SCREENING;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; MORTALITY; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM;

EID: 84881034311     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22680     Document Type: Article

References (26)

1. Moyer VA,. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157 (2): 120-134.
2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13): 1310-1319.
3. Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R,. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 23 (6): 827-835.
4. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A,. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56 (4): 584-591.
5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13): 1320-1328.
6. Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB,. The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines. Cancer 118 (23): 5955-5963.
7. Dennis LK, Resnick MI,. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42 (4): 247-252.
8. Feuer EJ, Merrill RM, Hankey BF,. Cancer surveillance series: interpreting trends in prostate cancer-Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91 (12): 1025-1032.
9. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS,. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91 (12): 1017-1024.
10. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD,. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004; 119 (2): 174-186.
11. Merrill RM, Brawley OW,. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997; 8 (2): 126-131.
12. Stephenson RA,. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29 (1): 173-181.
13. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ,. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007; 99 (18): 1395-1400.
14. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF,. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004; 64 (6): 1171-1176.
15. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2011 Sub, Vintage 2009 Pops (1973-2009) -Linked To County Attributes-Total U.S., 1969-2010. Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011.
16. Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seercancer.gov/seerstat) version 709).
17. Hudson DJ,. Fitting segmented curves whose join points have to be estimated. J Am Stat Assoc 1966; 61: 1097-1129.
18. Kim HJ, Fay MP, Feuer EJ, Midthune DN,. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19 (3): 335-351.
19. Yu B BM, Kim HJ, Feuer EJ,., Estimating joinpoints in continuous time scale for multiple change-point models. Comput Stat Data Anal 2007; 51 (5): 2420-2427.
20. Fay MP, Tiwari RC, Feuer EJ, Zou Z,. Estimating average annual percent change for disease rates without assuming constant change. Biometrics 2006; 62 (3): 847-854.
21. Potosky AL, Miller BA, Albertsen PC, Kramer BS,. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273 (7): 548-552.
22. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H,. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101 (6): 374-383.
23. Telesca D, Etzioni R, Gulati R,. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008; 64 (1): 10-19.
24. Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R,. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 64 (12): 1412-1417.
25. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J,. Prostate-cancer mortality in the USA and UK in 1975-2004: An ecological study. Lancet Oncol 2008; 9 (5): 445-452.
26. Kim HJ, Fay MP, Yu B, Barrett MJ, Feuer EJ,. Comparability of segmented line regression models. Biometrics 2004; 60 (4): 1005-1014.